

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 June 2004 (03.06.2004)

PCT

(10) International Publication Number
WO 2004/046095 A1

(51) International Patent Classification⁷: **C07C 335/26**,
C07D 207/16, 207/34, 209/48, 211/62, 211/70, 211/86,
213/65, 213/81, 215/06, 217/04, 233/90, 239/26, 257/04,
261/18

Allen Road, Winsor, CT 06095 (US). **OHKANDA, Junko**
[JP/US]; 572 Withney Avenue Apt. #E1, New Haven, CT
06511 (US). **LI, Shouming** [CN/US]; 6 Brookfield Court,
Cheshire, CT 06410 (US).

(21) International Application Number:
PCT/US2003/036809

(74) Agent: **REIMER, Leah, M.**; Cantor Colburn LLP, 55
Griffin Road South, Bloomfield, CT 06002 (US).

(22) International Filing Date:
18 November 2003 (18.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/427,634 19 November 2002 (19.11.2002) US

(71) Applicant (for all designated States except US):
ACHILLION PHARMACEUTICALS, INC. [US/US];
300 George Street, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEN, Dawei**
[CN/US]; 4132 Town Place, Middletown, CT 06457
(US). **DESHPANDE, Milind** [US/US]; 44 Field Brook
Road, Madison, CT 06443 (US). **THURKAUF, Andrew**
[US/US]; 163 Keeler Drive, Ridgefield, CT 06877 (US).
PHADKE, Avinash [IN/US]; 62 Montoya Drive, Bran-
ford, CT 06405 (US). **WANG, Xiangzhu** [CN/US]; 4
Brushy Plain Road Apt. #224, Branford, CT 06405 (US).
SHEN, Yiping [CN/US]; 92 Village Lane, Branford, CT
06405 (US). **LIU, Cuixian** [CN/US]; 4 Stoneridge Lane,
Branford, CT 06405 (US). **QUINN, Jesse** [US/US]; 55

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED ARYL THIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION

(57) Abstract: The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A1, A2, R1, R2, V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antiviral activity. The invention particularly provides compounds of Formula I that are potent and/ or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agent.